Effets transgénérationnels des perturbateurs endocriniens: les leçons du DES

Endocrine Disruptors and Lessons from DES Diethylstilbestrol

Pour plus d’information sur la journée tenue à l’Assemblée Nationale le 10 Avril 2012 vous pouvez lire cet article: Les Perturbateurs Endocriniens publié le 26 Avril dernier.

Intervention du Dr Annie J. Sasco, Médecin épidémiologiste du cancer, sur le thème “Effets transgénérationnels des perturbateurs endocriniens: les leçons du DES” lors de la table-ronde organisée par WECF le 10 avril sur le thème “Perturbateurs endocriniens, effets et mécanismes d’action de la conception à la maturité”.

Le Distilbène DES, en savoir plus

Endocrine Disruptors: DES Lessons

On Tuesday 10th April 2012, the French National Assembly hosted a debate around the harmful effects of endocrine disruptors to convince governments to take action.  French and foreign Endocrine Disruptors (ED) specialists attended the event, gave presentations and discussed the many issues associated with ED.  Among them was Dr. Annie J. Sasco , Cancer epidemiologist, INSERM Research Director, University of Bordeaux, France,  who worked on the transgenerational effects of endocrine disruptors, more specifically those of DES: “I am very pessimistic. For 30 years, cancer has doubled in the world. The DES tragedy is not enough. Even though DES was registered in 1939 in Britain on the poisons’ list, and it had been proven it was ineffective for the prevention of miscarriage since 1953, nothing prevented this drug from being widely produced and prescribed. It has been recognized as a carcinogenic drug since 1974, and it is now proven to have effects on the third generation in terms of risk of cancer, including ovarian and genital malformation rate 18 times higher than normal. We’ve just banned Bisphenol A in baby bottles yet the risks were known since the 30s. Another example is hormone replacement therapy: its extended use to 10 years of treatment is associated with an increased risk of cancer. ”

You can find more information about this debate by reading this article published on April, 26th (approximate translation by Google).

More DES DiEthylStilbestrol Resources

Diethylstilbestrol Clear Cell Adenocarcinoma Vaginal Cancer

Elevated risk for this type of cancer in DES Daughters as they age

DES and Cancer: the Never Ending Story

Diethylstilbestrol DES clear cell adenocarcinoma CCA vaginal cancer41 years ago, a connection between DES exposure and cancer in DES daughters was established.  Cases of Clear Cell Adenocarcinoma (CCA) of the vagina were diagnosed in an age group never before found to develop it. At the time the peak incidence of CCA in DES Daughters was in the late teens and early 20s. Most young women with CCA of the vagina have a history of prenatal exposure to diethylstilbestrol (DES). DES daughters were told by physicians that the risk was low when you reach your 30s and you can still read today on some websites that “if a DES daughter has not developed this cancer by age 30, she will not develop it”.

But today, DES daughters cancer fears are confirmed and justified as the findings and conclusions of a new report by CDC researchers suggest an elevated risk for this vaginal/cervical cancer in DES Daughters as they age.

When researchers first linked prenatal DES exposure to vaginal / cervical cancer in a small group of women, soon after, the Food and Drug Administration (FDA) notified physicians throughout the U.S.A. that DES should not be prescribed to pregnant women (note that it wasn’t banned!). In Europe, the drug continued to be prescribed to pregnant women until 1978. So even though this report says “elevated risk among women born between 1947 and 1971 in the United States”, it should read “among all women born between 1947 and 1978 in countries where DES was prescribed”. In the United States alone it is estimated that five to 10 million people were exposed to DES between 1938 and 1971.

When will this stop?  The statement “The more I learn the less I know” really seems to apply to the DES tragedy. As we learn more about the devastating health effects of diethylstibestrol, we begin to become more aware of the limits of our knowledge regarding the long term effects not only for DES daughters but also DES sons and the DES 3rd generation (children of DES daughters and sons). DES truly is a never ending story!

Wherever you are stay safe and remind your GP that DES daughters need yearly Pap test and pelvic exam as well as regular health screening and adequate care!

More DES DiEthylStilbestrol Resources